Ariel Sobarzo

ORCID: 0000-0002-2403-7305
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Viral Infections and Outbreaks Research
  • Viral Infections and Vectors
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 epidemiological studies
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Respiratory viral infections research
  • Vaccine Coverage and Hesitancy
  • Cancer Cells and Metastasis
  • Bacillus and Francisella bacterial research
  • Disaster Response and Management
  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • RNA modifications and cancer
  • Lung Cancer Diagnosis and Treatment
  • Mosquito-borne diseases and control
  • Traumatic Brain Injury Research
  • Lung Cancer Treatments and Mutations
  • Vector-Borne Animal Diseases
  • Influenza Virus Research Studies
  • Epigenetics and DNA Methylation
  • Ferroptosis and cancer prognosis
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Abdominal Trauma and Injuries

Ben-Gurion University of the Negev
2015-2024

Shaare Zedek Medical Center
2024

Ebola virus disease causes widespread and highly fatal epidemics in human populations. Today, there is still great need for point-of-care tests diagnosis, patient management surveillance, both during post outbreaks. We present a test comprising an immunochromatographic strip smartphone reader, which detects semiquantifies Ebola-specific antibodies survivors. developed Sudan glycoprotein monoplex platform validated it using sera from 90 survivors 31 local noninfected controls. The performance...

10.1021/acsnano.7b07021 article EN cc-by ACS Nano 2018-01-05

To better understand humoral immunity following ebolavirus infection, a serological study of the immune response against individual viral proteins Sudan (Gulu) in human survivors was performed. An enzyme-linked immunosorbent assay specific for full-length recombinant NP, VP30, VP40, and GP1–649 (GP lacking transmembrane domain) used as well plaque reduction neutralization test. Serum samples from survivors, which were collected up to 10 years recovery, screened analyzed. Results demonstrate...

10.1093/infdis/jit162 article EN The Journal of Infectious Diseases 2013-04-12

Immunotherapy using dendritic cell-derived exosomes (DEXs) represents an innovative strategy for cancer treatment. While cur-rent clinical monitoring methods, such as RECIST and iRECIST, provide tools evaluating outcomes through imaging clin-ical parameters, there remains a gap in comprehensive molecular evaluation of immunotherapy quality. This work reviews exist-ing develops integrated design that structures these into systematic protocol to optimize the de-velopment DEX-based therapies....

10.20944/preprints202501.0371.v1 preprint EN 2025-01-06

Dendritic exosomes (DEX) have demonstrated immunostimulatory potential in can-cer immunotherapy, but their clinical translation remains limited due to cryodepend-ence, heterogeneity, and poor scalability. To overcome these challenges, we developed a phospholipoprotein complex (PLPC), derived from dendritic cell secretomes sta-bilized via ultracentrifugation lyophilization. This study characterizes PLPC’s structural, immunological, functional properties compared conventional...

10.20944/preprints202504.0471.v1 preprint EN 2025-04-07

Effective management of foot and mouth disease (FMD) requires diagnostic tests to distinguish between infected vaccinated animals (DIVA). To address this need, several enzyme-linked immunosorbent assay (ELISA) platforms have been developed, however, these vary in their sensitivity specificity are very expensive for developing countries. Camelid-derived single-domain antibodies fragments so-called Nanobodies, demonstrated great efficacy the development serological diagnostics. This study...

10.3389/fvets.2018.00250 article EN cc-by Frontiers in Veterinary Science 2018-10-12

ABSTRACT Ebolavirus , a member of the family Filoviridae causes high lethality in humans and nonhuman primates. Research focused on protection therapy for Ebola virus infection has investigated potential role antibodies. Recent evidence suggests that antibodies can be effective from lethal challenge with However, despite these encouraging results, studies have not yet determined optimal composition an antibody cocktail, if required, which might serve as highly efficient prophylactic. To...

10.1128/cvi.00363-12 article EN Clinical and Vaccine Immunology 2012-09-19

Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of responses. Immune Ebola virus (EBOV) Sudan (SUDV) infections provided the most insight, T cell as well detailed antibody having been characterized. Marburg (MARV), however, remain almost entirely uncharacterized. We report that MARV share characteristics EBOV SUDV some...

10.1084/jem.20170161 article EN cc-by-nc-sa The Journal of Experimental Medicine 2017-07-19

Recovery from ebolavirus infection in humans is associated with the development of both cell-mediated and humoral immune responses. According to recent studies, individuals that did not survive ebolaviruses appear have lacked a robust adaptive response expression several early innate markers. However, comprehensive protective profile has yet be described. Here, we examine cellular memory responses among survivors two separate Ebolavirus outbreaks (EVDs) due Sudan virus (SUDV) Uganda—Gulu...

10.3390/v7010037 article EN cc-by Viruses 2015-01-06

Abstract Ebolavirus is a highly lethal pathogen, causing severe hemorrhagic disease with high fatality rate. To better understand immune correlates of protection by virus specific IgG, we investigated the evolution Fcγ receptors (FcγRs)-activating capabilities antiviral IgG in serum samples long recovered survivors. this end, longitudinal from survivors Sudan ebolavirus (SUDV) infection, studied over years, were examined for presence Ebola-GP subclasses, and their binding to FcγRs. We...

10.1038/s41598-017-06226-8 article EN cc-by Scientific Reports 2017-07-14

In the pursuit of creating personalized and more effective treatment strategies for lung cancer patients, Patient-Derived Xenografts (PDXs) have been introduced as preclinical platforms that can recapitulate specific patient's tumor in an vivo model. We investigated how well PDX models preserve tumor's clinical molecular characteristics across different generations.

10.1007/s12094-024-03450-3 article EN cc-by Clinical & Translational Oncology 2024-03-29

Robust humoral and cellular immunity are critical for survival in humans during an ebolavirus infection. However, the interplay between these two arms of is poorly understood. To address this, we examined residual immune responses survivors Sudan virus (SUDV) outbreak Gulu, Uganda (2000–2001). Cytokine chemokine expression levels SUDV stimulated whole blood cultures were assessed by multiplex ELISA flow cytometry. Antibody corresponding neutralization titers also determined. Flow cytometry...

10.3390/v8050133 article EN cc-by Viruses 2016-05-11

Objectives The aims of this study were to evaluate associations between abnormal head CT findings and outcome, examine the prognostic value Koret score (KCTS) in cats sustaining acute traumatic brain injury (TBI). Methods medical records hospitalised with TBI that underwent scans within 72 h admission retrospectively reviewed. evaluated independently by a radiologist neurologist who blinded outcome. A KCTS modified Glasgow Coma Scale (MGCS) assigned each cat association findings, KCTS, MGCS...

10.1177/1098612x211005306 article EN cc-by-nc Journal of Feline Medicine and Surgery 2021-04-13

<title>Abstract</title> Humanized mouse models based on PBMC transplants have become a critical preclinical platform for NSCLC investigation. However, the emergence of xeno-GVHD poses challenges that need clarification. In this study, we explore clinical and molecular aspects induced by patient PBMCs compared to healthy donors in novel NSG-SGM3 mice. from patients were injected into mice monitored eight weeks assess onset progression. Clinical signs, such as weight loss, anemia, low platelet...

10.21203/rs.3.rs-4086903/v1 preprint EN cc-by Research Square (Research Square) 2024-03-28

Cancer represents one of the most complex medical challenges our time. Over decades, standard approaches have included combination surgery, chemotherapy, and radiotherapy. While effective in many cases, these strategies significant limitations, particularly when time becomes a critical factor [1]. One controversial areas modern oncology is decision to delay surgery certain cancers, such as colon, breast, other solid tumors, favor prolonged neoadjuvant chemotherapy [2]. This strategy,...

10.47363/jmhc/2024(6)290 article EN Journal of Medicine and HealthCare 2024-12-26

Abstract Despite the widespread utilization of Patient-Derived Xenografts (PDXs) as preclinical platforms in lung cancer research, there are concerns regarding their capability to accurately represent tumor's clinical and molecular features across sequential passages. In this study, we established a Non-Small Cell Lung Cancer (NSCLC) PDX model NSG-SGM3 mice assessed factors throughout subsequent Our cohort consisted 40 NSCLC patients, which were used successfully create 20 patient-specific...

10.21203/rs.3.rs-2569321/v1 preprint EN cc-by Research Square (Research Square) 2023-03-10

The critical issues of sustained memory immunity following ebolavirus disease among long-term survivors are still unclear.

10.1093/infdis/jiad555 article EN The Journal of Infectious Diseases 2023-12-07

Abstract From 2011 to the present, there have been four confirmed filovirus outbreaks with a fifth case involving single patient. Four outbreaks/cases were attributed Ebolavirus genus, Marburgvirus responsible for one. With high lethality rates seen in these (generally ~40-90%), and potentially dramatic disease sequelae, can devastate local communities present great health risks affected regions. These issues obviate need effective vaccines therapeutics limit manage future outbreaks. In 2012...

10.4049/jimmunol.192.supp.208.12 article EN The Journal of Immunology 2014-05-01

correction hemagglutinin leukoagglutinin.There were no differences in complete blood count, general medical history, or treatment during infection among persons who had been infected with Ebola virus.Results of ELISA IgG against inactivated SUDV-gul and GP 1-649 revealed that all survivors tested positive for both .No immunoreactivity was observed the noninfected control group.PRNT 80 results showed survivor group, four neutralization two negative.All serum samples obtained from not...

10.1056/nejmx130034 article EN New England Journal of Medicine 2013-07-11
Coming Soon ...